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Letter to the EditorAllergoOncology: Generating a canine
anticancer IgE against the epidermal
growth factor receptorTo the Editor:
Cancer immunotherapy with antibodies has revolutionized
clinical oncology, giving hope for patients with cancer. Among
these, cetuximab, a mouse-human chimeric antibody, targeting
the human epidermal growth factor receptor (EGFR),1 inhibits
growth signaling and mediates antibody-dependent cell-mediated
cytotoxicity (ADCC) and antibody-dependent cellular phagocy-
tosis (ADCP)E5,2 of tumor cells. Harnessing TH2 immune re-
sponses against cancer is a subject in the emerging field of
‘‘AllergoOncology,’’ taking advantage of the high capacity of
IgE to trigger immune reactions against cancer.3 Unlike Fcg-re-
ceptors, all Fcε-receptors are activating.3 Because fewer than 1
in 10 anticancer drugs translate from murine preclinical studies
to human clinical trials,4 we focused on dogs (Canis lupus famil-
iaris) with spontaneously occurring cancer as potential efficacy
models. Mammary carcinomas and osteosarcomas in dogs and
humans frequently overexpress EGFR.4,5 Also, human and canine
immune systems are highly similar,3 rendering canine clinical tri-
als a promising alternative to rodent experiments.
We previously developed a caninized cetuximab IgG, ‘‘can225-
IgG,’’6 which here we engineered into cetuximab IgE, ‘‘can225-
IgE-l,’’ retaining the exact epitope specificity, but with the
canine l- and ε-constant domains. Can225IgE-l was cloned us-
ing a ligation-free cloning techniqueE13 and expressed in
Expi293F cells on the basis of our previously published method7
(Fig 1, A; see this article’s Methods section in the Online Repos-
itory at www.jacionline.org). The affinity-purified can225IgE-l
had an apparent molecular mass of 235 kDa (Fig 1, B) and was
correctly assembled (Fig 1, C and D) with low amounts of free
chains.
We confirmed antibody specificity to recombinant human
EGFR by Western blot (Fig 1, E), to native EGFR on human
A431 breast cancer cells (Fig 1, F), to P114 canine mammary
carcinoma (Fig 1, G) and D17 canine osteosarcoma (Fig 1, H)
cells, but no binding to EGFR-negative CHO K1 (control) cells
(Fig 1, I).
Next, we assessed FcεRI expression on effector cell lines. Both
human promonocytic U937 and canine monocytic/macrophage-
like DH82 cells showed moderate to high FcεRI expression
(Fig 1, J and K). Furthermore, canine MPT-1 mast cells showed
relatively lower FcεRI expression (Fig 1, L) compared with
RBL-SX38 rat basophilic leukemia cells transfected with human
tetrameric FcεRI (Fig 1, M). Because no cross-reactive antibody
for canine FcεRII (CD23) was available, we evaluated CD23
expression on canine effector cell lines by RT-PCR. We observed
a more than 1000-fold higher relative CD23 expression by MPT-
1, compared with DH82 cells (Fig 1, N). The can225IgE-l anti-
body bound to Fcε receptors on U937 cells (Fig 2, A),
DH82 cells (Fig 2, B), and MPT-1 (Fig 2, C) cells.Crown copyright  2018 Published by Elsevier Inc. on behalf of the American
Academy of Allergy, Asthma & Immunology. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Having shown tumor target specificity and recognition of
immune effector cells by can225IgE-l, we next used a tumor cell
killing assayE4 to quantify immune-mediated tumor cell killing by
can225IgE-l via flow cytometry. Tumor cells killed by cytotox-
icity (ADCC) and phagocytosis (ADCP) were counted separately
(for gating strategy, see Fig E1, A, in this article’s Online Repos-
itory at www.jacionline.org).We first used human A431 as cancer
target cells, U937 as effector cells, and human and dog cetuximab
IgGE5 and IgE versions. Both cetuximab IgG and IgE showed
high tumor cell killing potential, mostly via ADCC (Fig 2, D)
mediated by effector cells.
Canine IgE shows a 33 times weaker binding strength to the
human FcεRI compared with human IgE. Accordingly, can225-
IgE-l–triggered tumor killing with human effector cells was
significantly lower than that triggered by human cetuximab-IgE
(Fig 2, E). None of the antibodies had a significant effect on the
ADCP of tumor cells (see Tables E1 and E3 in this article’s Online
Repository at www.jacionline.org).
We furthermore evaluated whether can225IgE-l could activate
canine effector cells (Fig 2, F and G; Table E1). In a time-
dependent manner (Fig E1, K), can225IgE-l triggered signifi-
cantly higher levels of ADCC by canine DH82 macrophages
compared with can225IgG (Fig 2, F). Conversely, and in agree-
ment with previous studies,E7,8 can225IgG was significantly su-
perior to IgE with regard to triggering tumor cell ADCP (see
Table E4 in this article’s Online Repository at www.jacionline.
org).
In addition, we investigated the effects of an approach using
50:50 can225IgG and can225IgE-l at the same total antibody
amount as samples treated with individual antibodies. Combina-
tional treatment performed comparable tumor cell ADCC to that
by can225IgE-l alone, but significantly better ADCC than that by
can225IgG alone. ADCP was lower than that triggered by
can225IgG, but higher than in can225IgE-l monotherapy
(Fig 2, F).
Overall, can225IgE-lmediated higher levels of total tumor cell
killing compared with those mediated by can225IgG alone.
Moreover, combining can225IgG and can225IgE-l was signifi-
cantly superior to each isotype alone (Fig 2, G; see Table E2 and
Table E4 in this article’s Online Repository at www.jacionline.
org).
Similarly, we evaluated the cytotoxic killing potency of
can225IgE-l by MPT-1 canine mast cells against A431 and
measured specific tumor cell killing (Fig 2, H). Although ADCP
assessment by flow cytometry was not possible in this experi-
mental setting due to cell clumping, we could indeed confirm
mast cell–mediated ADCC by fluorescence microscopy
(Fig 2, I). Such effector functionsmay be due to can225IgE-l spe-
cifically binding to IgE receptors (FcεRI on RBL-SX38 cells, Fig
2, J) and canine CD23, expressed on transfected CHO K1 cells
(Fig 2, K).
Therefore, we established an in vitro system for quantification
and side-by-side comparison of anticancer ADCC/ADCP trig-
gered by cetuximab IgG, IgE, and their canine counterparts. Un-
like in humans where k:l light chains are expressed in a ratio of
2:1, the average k:l ratio in dogs is 1:9.E11 Hence, we engineered
can225IgE-l. Because canine IgE is able to bind human FcεRI,
we could demonstrate dose-dependent binding of can225IgE-l1
FIG 1. Expression and characterization of can225IgE-l, and IgE-receptor expression on effector cell lines.
Expression vector construct (A), can225IgE-l on a silver-stained protein gel (B), and western blot developed
with antidog IgE (Fc) (C) andwith antidog light chain (D). Binding of can225IgE-l to human EGFR byWestern
blot (E) and to EGFR on human and canine target cell lines using EGFR-negative cell line CHO K1 for control
(F-I). FcεRI expression on human and canine effector cell lines (J-M) and relative CD23 expression of MPT-1
canine mast cells compared with DH82 monocytic/macrophage-like cells, normalized to beta-actin expres-
sion (N). CMV, Cytomegalovirus; HER-2, epidermal growth factor receptor 2; PE, phycoerythrin; SV40, sim-
ian vacuolating virus 40.
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canine FcεRI on DH82 andMPT-1 cells (Fig 2, B andC). Further-
more, we showed that DH82 macrophages express low levels of
CD23 (Fig 1, N), but high levels of functional FcεRI (Fig 1, K),
which is likely responsible for triggering IgE-mediated tumor
cell killing (Fig 2, F and G), comparable to that mediated by hu-
man U937 monocytic effector cells. Using the canine DH82 mac-
rophages, we were able to generate a species-relevant in vitro
model systemwith which we confirmed the tumoricidal potencies
of our canine antibodies, can225IgG or can225IgE-l, alone, or
combined.
It has been observed that human IgG triggers considerable
levels of ADCP, whereas IgE mainly elicits ADCC by human
monocytes/macrophages.E7,8 We observed the same in the dog
system and we also report significantly higher total tumor cell
killing induced by IgE.We furthermore anticipated that IgE could
act complementary to IgG, through using different Fc-receptorson effector cells. Coincubation with can225IgG and can225IgE-l
exerted higher tumor cell death, than did IgG or IgE treatment
alone (Fig 2, F). Finally, we also demonstrate that can225IgE-l
is able to trigger specific ADCC against EGFR1 tumor cells by
canine MPT-1 mast cells (Fig 2, H and I).
Additional studies are needed to further evaluate these
promising results with other IgG or IgE effector cells.3,9
This study presents the first in vitro functionally active canine
anticancer IgE antibody for future clinical studies in dog cancer
patients that may offer new options in cancer immunotherapy.9
Judit Fazekas-Singer, MSca,b
Josef Singer, MD, PhDa,b,c
Kristina M. Ilieva, MScd,e,f
Miroslawa Matz, MScb
Ina Herrmann, DVMa,g
Edzard Spillner, PhDh
Sophia N. Karagiannis, PhDd,e
Erika Jensen-Jarolim, MDa,b
FIG 2. Functional characterization of can225IgE-l. Dose-dependent binding of can225IgE-l to Fcε-receptors
on U937 human promonocytic cells (A), DH82 canine monocytic/macrophage-like cells (B), and MPT-1
canine mast cells (C), with left panels depicting fluorescence histograms and right panels quantified delta
mean fluorescence intensity values (n 5 3). ADCC- and ADCP-triggering potency (D) and total tumor cell
killing (E) induced by can225IgE-l compared with other antibodies with human U937 cells and human
A431 tumor cells as targets. ADCC- and ADCP-triggering potency (F) and total tumor cell killing (G) of
can225IgE-l compared head-to-head to its IgG counterpart can225IgG and to a combinatory
can225IgG 1 IgE-l treatment, using canine DH82 cells as effectors and A431 tumor cells as targets.
ADCC-triggering potency of can225IgE-l using canine MPT-1 mast cells as effector cells and human A431
as target cells (H). Microscopic image of the ADCC assay depicted in panel H: can225IgE-l–mediated cyto-
toxic killing of A431 cells (green) by MPT-1 mast cells (red) using DAPI (blue) as an indicator of dead cells
(white arrowheads) (I). Receptor-specific binding of can225IgE-l to FcεRI expressed on RBL-SX38 cells (J)
and to canine CD23 on transfected CHO K1 cells (K). DAPI, 49-6-Diamidino-2-phenylindole, dihydrochloride.
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RESULTS AND DISCUSSION
Affinity purification of can225IgE-l
In contrast to previous reports,E1 we did not succeed in purify-
ing can225IgE-l by Protein A affinity columns. This might be
possibly due to 2 IgE isoforms in dogs, IgE1 having a high affinity
toward Staphylococcal Protein A and IgE2 not at all binding to
protein A.E2
ADCC and ADCP assay using EGFR- CHO K1 as
target cells
The EGFR-negative CHO K1 cell line was used as control
target cells. These cells were not recognized by can225IgE-l (Fig
1, I). Consequently, CHO K1 cells were also not attacked by the
human monocytic U937 cells (Fig E1, C and D) or the canine
monocytic/macrophage-like DH82 cells (Fig E1, E and F).
Phenotypical characterization of DH82 and MPT-
1 cells
DH82 cells appeared as single, round cells in culture and
showed only 1 distinct population in flow cytometry scatter plots
(Fig E1, B); 77.4% of DH82 cells were positive for CD16 (DMFI,
713), 99.9% for CD14 (DMFI, 12922), and 72.2% for CD80
(DMFI, 2797) (Fig E1, G-I).
DH82 cells transform over time from a monocyte- to a
macrophage-like phenotype, associated with changes in CD14
and CD80 surface marker expression.E3 However, both CD14 and
CD80 expression levels, as well as morphology and the uniform
population in flow-cytometric scatter plots, identified a mono-
cytic phenotype,E3 which was advantageous because the 3-color
flow-cytometric assay had been established for monocytes.E4
METHODS
For proof-of-concept studies in the field of comparative immuno-oncology
and AllergoOncology, the recombinant canine IgE antibody can225IgE-lwas
developed against EGFR, which has 95% amino acid sequence homology and
92% identity among humans and dogs.E5 The antibody was expressed in a
transient expression system and characterized with respect to correct assem-
bly, EGFR specificity, and binding to IgE receptors FcεRI and CD23. In addi-
tion, the functionality of can225IgE-l was evaluated in a flow-cytometric
ADCC and ADCP assay using human and canine monocyte-like cells, as
well as canine mast cells as effectors against EGFR-overexpressing tumor
and EGFR-negative control cells, as described below.
Cell lines, antibodies, and antigens
Cell lines. Human monocytic cell line U937 (CRL-1593.2), human
epidermoid carcinoma cell line A431 (CRL-1555), canine osteosarcoma cell
line D17 (CCL183), canine monocyte/macrophage-like cell line DH82 (CRL-
10389), and Chinese hamster ovary cell line CHO K1 (CCL-61) were
purchased from the American Type Culture Collection (Manassas, Va).
Canine mammary carcinoma cell line P114 was a kind gift of G. Rutteman,
University of Utrecht (Utrecht, The Netherlands). Canine mast cell line MPT-
1E6 was a kind gift of Prof. H. Matsuda, Tokyo University of Agriculture and
Technology (Tokyo, Japan). U937was cultured in RPMI 1640GlutaMAXme-
dium (Gibco, Thermo Fisher Scientific, Waltham, Mass) supplemented with
10% (v/v) FBS (Gibco, Thermo Fisher Scientific) and 100 U/mL penicillin
and 100 mg/mL Streptomycin (Gibco, Thermo Fisher Scientific). A431 was
grown in high glucose (4.5 g/L) Dulbecco modified Eagle medium
(DMEM) GlutaMAX medium (Gibco, Thermo Fisher Scientific), supple-
mented with 10% FBS and 100 U/mL penicillin and 100mg/mL streptomycin.
D17 was grown in Minimum Essential Medium (MEM) GlutaMAX (Gibco,
Thermo Fisher Scientific), augmented with 10%FBS and 100 U/mL penicillin
and 100 mg/mL streptomycin. P114 was cultured in DMEM/F-12 GlutaMAX
(Gibco, Thermo Fisher Scientific) media supplemented with 10% FBS and
100 U/mL penicillin and 100 mg/mL streptomycin. DH82 was cultured in
low glucose (1 g/L) DMEM GlutaMAX medium (Gibco, Thermo Fisher Sci-
entific), supplemented with 10% FBS and 100 U/mL penicillin and 100 mg/
mL streptomycin. MPT-1 was grown in alpha-MEM GlutaMAX medium
(Gibco, Thermo Fisher Scientific), supplemented with 10% FBS and 100 U/
mL penicillin and 100 mg/mL streptomycin. CHO K1 was grown in Ham’s
F-12 Nutrient Mix GlutaMAX (Gibco, Thermo Fisher Scientific), augmented
with 0% FBS and 100 U/mL penicillin and 100mg/mL streptomycin. All cells
were maintained in a humidified incubator at 378C under a 5% CO2
atmosphere.
Antibodies. Cetuximab (Erbitux) was purchased from Merck (Darm-
stadt, Germany). Rituximab (MabThera) was used as human IgG isotype
control andwas purchased fromRoche (Basel, Switzerland). Cetuximab IgEE7
was provided by Dr E. Spillner, Aarhus University (Aarhus, Denmark).
MOv18-IgEE8—used as human IgE isotype control—was provided by Dr
S.N. Karagiannis and Prof. H.J. Gould, King’s College London (London,
UK). Purified canine IgG (cat# IR-DG-GF, Innovative Research, Novi,
Mich) was used as canine IgG isotype control and purified canine IgE (cat#
P115, Bethyl Laboratories, Montgomery, Tex) as canine IgE isotype control.
Can225IgG was produced as described by Singer et al.E9
Antigens. Recombinant human EGFR (extracellular domain) was pur-
chased from ACROBiosystems (cat# EGR-H5222). Recombinant human
epidermal growth factor receptor 2 (extracellular domain) was produced in-
house by Lec-1 cells,E10 which were a kind gift of D. Leahy from Johns Hop-
kins University School of Medicine (Baltimore, Md).
Cloning of can225IgE-l
Cetuximab heavy-chain variable region sequence was fused with the canine
immunoglobulin epsilon constant sequence (NCBI GenBank: AAA56797.1).
Cetuximab light-chain variable region sequence was fused with the canine
lambda (because of its higher prevalence in dogs than in humans).E11 The
light-chain constant sequence (NCBI Ref Seq: XP_013963655.1) can be found
among the coding sequences in Table E5. The final sequences were synthesized
by GeneArt in Strings DNA format (Thermo Fisher Scientific) and cloned into
pCR-Blunt vector using Zero Blunt PCR Cloning Kit (Thermo Fisher Scienti-
fic). Coding sequenceswere recloned into pVitro1-hygro (Invivogen, SanDiego,
Calif) using a ligation-free polymerase incomplete primer extension cloning
method adapted from Dodev et al.E12 All primers used for polymerase incom-
plete primer extension cloning are listed in Table E6. The pVitro-hygro-can225-
IgE-l construct was then transformed into Escherichia coli Top10 (Thermo
Fisher Scientific). Correct clones were verified using Sanger sequencing.
Production and purification of can225IgE-l
Can225IgE-l was produced according to Ilieva et alE13 in human
Expi293F cells using the pVitro1 vector (Fig 1, A) and purified with a custom
affinity column using the €AKTAFPLC system from GE Healthcare Life Sci-
ences (Chicago, Ill). Custom anti-dog IgE column was made by crosslinking
1 mg goat anti-dog IgE (cat# NB7343, Novus Biologicals, Littleton, Colo) to
HiTrap Protein GHP column (GEHealthcare Life Sciences) in the presence of
50-fold molar excess disuccinimidylsuberate (Sigma-Aldrich, St Louis, Mo).
PBS, pH 7.4, was used as binding and washing buffer. Bound can225IgE-l
was then eluted with 0.1 M glycine (pH 2.5) followed by immediate pH
neutralization using 1 M tris-HCl, pH 8.0.
PAGE and immunoblots
PAGE was run using tris-glycine–based 4% to 20%Mini-PROTEAN TGX
gels (Bio-Rad Laboratories, Hercules, Calif), Laemmli loading buffer, and
molecular weight markers Spectra Multicolor High Range Protein Ladder
(Fig 1, B-D) and PageRuler Plus Prestained Protein Ladder (Fig 2, A) from
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Thermo Fisher. The gels were loadedwith 0.5mg can225IgE-l/canine IgE iso-
type or 1 mg recombinant human EGFR/recombinant human epidermal
growth factor receptor 2/BSA and the proteins were subsequently detected
either by silver staining or by immunoblot. Blocking and antibody dilutions
were performed with 5% (w/v) skimmed milk powder dissolved in tris buff-
ered saline, pH 7.2, 1 0.1% (v/v) tween-20. Canine IgE was detected using
horseradish peroxidase–labeled goat anti-dog IgE (cat# 7346, Novus Biolog-
icals) at 1:5000 for 1 hour, or by 0.5 mg/mL can225IgE-l for 2 hours at room
temperature. Blots were developed with Clarity Western enhanced chemilu-
minescence substrate (Bio-Rad) using the VersaDoc Imaging System (Bio-
Rad). Light chains were detected using 0.5 mg/mL anti-dog light-chain anti-
body (cat# A40-124A, Bethyl Laboratories) followed by alkaline
phosphatase-labeled donkey anti-goat IgG detection antibody (cat# A16008,
Thermo Fisher) at 1:2000, and subsequently visualized using 1-Step NBT/
BCIP substrate solution (Thermo Fisher).
Determination of the molecular mass
The apparent molecular mass of can225IgE-l on silver-stained PAGE was
determined using GelAnalyzer 2010a software (Istvan Lazar and Dr Istvan
Lazar). Spectra Multicolor High Range Protein Ladder (Thermo Fisher
Scientific) was used as a reference.
Flow-cytometric binding assays
Specificity testing. A431, D17, P114, and CHOK1 cells were detached
using Accutase solution (Sigma-Aldrich). A total of 3 3 105 cells/tube were
stained with 10 mg/mL can225IgE-l (or isotype control) for 30 minutes on
ice followed by 10 mg/mL fluorescein isothiocyanate (FITC)-labeled goat
anti-dog IgE (cat# NB7345, Novus Biologicals) for 30 minutes on ice in a
light-protected environment. The cells were analyzed on a 3-laser FACSCanto
II flow cytometer (BD Biosciences, Franklin Lakes, NJ).
FcεRI staining of effector cells. DH82 and MPT-1 (3 3 105 per test)
were stained with 10 mg/mL phycoerythrin-labeled anti-mouse FcεRI (clone
MAR-1) (cat# 12-5898-83, eBioscience, Santa Clara, Calif) or appropriate
isotype controls. U937 and RBL-SX38 cells (3 3 105 per test) were stained
with 10 mg/mL anti-human FcεRI (clone CRA-1) (cat# 14-5899-82, eBio-
science, Santa Clara, Calif), or mouse IgG2b isotype control, detected by
10 mg/mL FITC-labeled goat anti-mouse IgG (cat# F0479, DAKO, Agilent
Technologies, Santa Clara, Calif).
Fc-binding assay. U937, DH82, andMPT-1 cells (33 105 per test) were
incubated with can225IgE-l at different concentrations (1, 2.5, 5, and 10 mg/
mL) for 30 minutes at 378C. Bound can225IgE-lwas detected with 10mg/mL
FITC-labeled goat anti-dog IgE.
Receptor-specific binding of can225IgE-l. RBL-SX38 or canine
CD23-transfected CHOK1 cells (33 105 per test) were incubated with 10mg/
mL can225IgE-l for 30minutes. Following awashing step, bound can225IgE-
l was detected with 10 mg/mL FITC-labeled goat anti-dog IgE.
Characterization of DH82 cells. DH82 cells (passages 16-27, 33 105
per test) were stained with APC-labeled anti-human CD14 clone T€uk4 (cat#
MHCD1405, Thermo Fisher)/FITC-labeled anti-human CD16 (clone LNK16)
(cat# MA1-19611, Thermo Fisher)/phycoerythrin-labeled anti-mouse CD80
(clone 16-10A1) (cat# 12-0801-82, eBioscience), or the respective controls.
Cells were incubated with antibodies at concentrations according to the manu-
facturer’s instructions for 30 minutes and washed before acquisition.
Real-time PCR analysis of canine CD23 expression
Total RNA of 5 3 106 DH82 and MPT-1 was isolated using the RNeasy
Mini Kit (cat# 74104, Qiagen, Venlo, The Netherlands) and transcribed using
the SuperScript II reverse transcriptase (cat# 18064022, Thermo Fisher) along
with oligo(dT)12-18 primers (cat# 18418012, Thermo Fisher) according to the
manufacturer’s instructions. Real-time PCR was performed using SYBR
Green PCRMaster Mix (cat# 4309155, Applied Biosystems, Thermo Fisher).
Primers for canine CD23: forward: CCCAGAGCTTGAACGAGAGAA,
reverse: TCCTCGCCGAAGTAGTAGCAC, as described by Amagai et al.E6
Primers for beta-actin: forward: ATTGCCGACAGGATGCAGAA, reverse:
GCTGATCCACATCTGCTGAA. RT-PCR analysis was performed using 3
biological replicates (and 3 technical replicates of each biological replicate).
3-Color flow-cytometric ADCC and ADCP assay
Flow-cytometric ADCC/ADCP assays were performed using the method
described by Bracher et al.E4 A431 tumor cells were prestained with 5 mM of
the greenfluorescent dye carboxyfluoresceinsuccinimidyl ester for 10minutes,
18 hours before the experiment. The tumor cells (70000/test) were incubated
with 5mg/mL antibody solution in assay buffer (RPMI 1640 GlutaMAX12%
(v/v) FBS) at 378C for 30 minutes. Next, 210,000 U937 cells/tube were coin-
cubated with the tumor cells at 378C for 2.5 hours. Following the incubation,
U937 were labeled with APC-conjugated anti-human CD89 antibody (cat#
354106, BioLegend, San Diego, Calif). Dead cells were detected using the
blue fluorescent DNA dye 49,6-diamidino-2-phenylindole (cat# D1306,
Thermo Fisher), few seconds before acquisition on the FACSCanto II.
When using DH82 or MPT-1 as effector cells, both tumor and effector cells
were stained with cell-tracking dyes 18 hours in advance to the treatment
antibodies and coincubation: Tumor cells were prestained with carboxyfluor-
esceinsuccinimidyl ester (as described earlier), whereas DH82 and MPT-1
were prestainedwith 1mMCellTrace Far Red (Thermo Fisher) for 10minutes.
Because effector cells were already prelabeled in this case, no CD89 staining
was needed to tag the cells after the coincubation of the tumor and effector
cells. All assays were performed at least 3 times using 3 technical replicates
per condition. Data were analyzed using FlowJo V10.0.7 (Flow Jo LLC,
Ashland, Ore).
Fluorescence microscopy
Samples were prepared as described in the 3-color flow-cytometric ADCC
andADCP assay section usingMPT-1 caninemast cells and A431 tumor cells.
Fifteenmicroliter of the nonfixed cell suspension wasmounted on a glass slide
immediately after 49,6-diamidino-2-phenylindole staining, and fluorescence
microscopy pictures were recorded 20 minutes within mounting using an
Axioplan 2 fluorescent microscope (Carl Zeiss Microscopy GmbH, Jena,
Germany) with a 203 air objective.
Generation of canine CD23-expressing CHO K1 cells
CHO K1 cells were transfected with pcDNA3.3-TOPO (Thermo Fisher)
containing the coding sequence of canine CD23 (back-translated from the
amino acid sequence disclosed under GenBank accession number
AAN20273.1) using Lipofectamine 3000 (Thermo Fisher) according to the
manufacturer’s instructions. Forty-eight hours after transfection, 1 mg/mL
G418 (cat# CP11.3, Carl Roth) was added and selection pressure was main-
tained over 3 weeks before proceeding to IgE-binding assays.
Statistical analyses
Statistical analyses were carried out using GraphPad Prism v5.00 for
Windows (GraphPad Software, Inc, La Jolla, Calif). Fig 2, A-C, shows mean
values1 SEM, and Fig 2,D-H, and Fig E1,C-F, depict mean1 SD. To calcu-
late the statistical significance of induced killing between the different treat-
ment groups (Table E3 and Table E4), we used 2-way ANOVA with
Bonferroni posttest (phagocytosis and cytotoxicity). To compare the total
killing induced by the antibodies (Fig 2, E and G, and Fig E1, D and F), we
used 1-way ANOVA followed by Tukey multiple comparison test. Statistical
significances are defined as *P < .05, **P < .01, and ***P < .001.
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FIG E1. Gating strategies, ADCC and ADCP control assays, and phenotypical characterization of effector
cells. Gating strategy in flow-cytometric ADCC and ADCP assays (A) and DH82 cell characterization (B).
ADCC- and ADCP-triggering potency (C) and total tumor cell killing (D) induced by can225IgE-l compared
with other antibodies in a negative control assay using U937 as effector and EGFR-negative CHO K1 as
target cells. ADCC- and ADCP-triggering potency (E) and total tumor cell killing (F) induced by can225IgE-
l compared with other antibodies in a negative control assay using DH82 as effector and EGFR-negative
CHO K1 as target cells. DH82 cell characterization in regard of CD16 (G), CD14 (H), and CD80 (I) expression,
pointing toward a monocyte-like phenotype. Negative control experiment to Fig 2, K: nontransfected
(parental) CHO K1 did not bind can225IgE-l (J). Evaluating IgE-mediated tumor cell killing over time
confirmed previous literature reporting 2.5 hours as the optimal incubation time (K). CFSE, Carboxyfluores-
ceinsuccinimidyl ester; FSC-A, forward scatter-area; ns, nonsignificant; SSC-A, side scatter-area.
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TABLE E1. ADCC and ADCP triggered by different antibody treatments
U937 as effector cells
Killing mechanism PBS Human IgG ISO Cetuximab IgG Human IgE ISO Cetuximab IgE Dog IgE ISO can225IgE-l
Cytotoxicity 20% 6 6.0% 18% 6 5.0% 56% 6 8.6% 18% 6 5.2% 68% 6 4.7% 18% 6 4.0% 55 % 6 14%
Phagocytosis 4.0% 6 2.3% 3.3% 6 2.4% 5.3% 6 4.3% 4.4% 6 4.0% 4.2% 6 3.3% 3.7% 6 2.9% 3.6% 6 3.4%
DH82 as effector cells
Killing mechanism PBS Dog IgG ISO can225IgG Dog IgE ISO can225IgE-l Dog IgG 1 dog IgE ISO can225IgG 1 can225IgE-l
Cytotoxicity 15% 6 2.3% 13% 6 1.7% 40% 6 4.9% 14% 6 2.4% 64% 6 3.4% 15% 6 2.8% 63% 6 5.1%
Phagocytosis 18% 6 2.3% 19% 6 2.9% 28% 6 2.6% 19% 6 2.5% 11% 6 1.3% 19% 6 1.1% 18% 6 2.5%
Depicted are mean values 6 SDs in percent of the total number of tumor cells in the sample. n 5 9 in all groups except combinational treatment with dog IgG and IgE isotype
control and can225IgG1IgE, where n 5 6.
ISO, Isotype control antibody; PBS, phosphate buffered saline, mock-treated control.
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TABLE E2. Total tumor cell killing triggered by different antibody treatments
U937 as effector cells
Treatment PBS Human IgG ISO Cetuximab IgG Human IgE ISO Cetuximab IgE Dog IgE ISO can225IgE-l
Total killing 24% 6 6.0% 21% 6 5.2% 61% 6 12% 22% 6 6.1% 72% 6 7.5% 21% 6 5.0% 58% 6 16%
DH82 as effector cells
Treatment PBS Dog IgG ISO can225IgG Dog IgE ISO can225IgE Dog IgG 1 dog IgE ISO can225IgG 1 can225IgE-l
Total killing 32% 6 2.9% 32% 6 3.6% 67% 6 3.8% 32% 6 1.6% 74% 6 2.6% 34% 6 1.9% 82% 6 3.1%
Depicted are mean values 6 SDs in percent of the total number of tumor cells in the sample. n 5 9 in all groups except combinational treatment with dog IgG and IgE isotype
control and can225IgG1IgE, where n 5 6.
ISO, Isotype control antibody; PBS, phosphate buffered saline, mock-treated control.
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TABLE E3. Detailed statistical analysis of antibody treatments in ADCC and ADCP assays using the human U937 as effector cells
Phagocytosis Y
Cytotoxicity/
PBS Human IgG ISO Cetuximab IgG Human IgE ISO Cetuximab IgE Dog IgE ISO can225IgE
PBS ns *** ns *** ns ***
Human IgG ISO ns *** ns *** ns ***
Cetuximab IgG ns ns *** *** * ns
Human IgE ISO ns ns ns *** ns ***
Cetuximab IgE ns ns ns ns *** ***
Dog IgE ISO ns ns ns ns ns ***
can225IgE ns ns ns ns ns ns
Statistical analysis was calculated by 2-way ANOVA and Bonferroni posttest. Significance is determined as following: ns, nonsignificant (P > .05).
*P < .05.
***P < .001.
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TABLE E4. Detailed statistical analysis of antibody treatments in ADCC and ADCP assays using the canine DH82 as effector cells
Phagocytosis Y
Cytotoxicity/
PBS Dog IgG ISO can225IgG Dog IgE ISO can225IgE Dog IgG 1 dog IgE ISO can225IgG 1 can225IgE
PBS ns *** ns *** ns ***
Dog IgG ISO ns *** ns *** ns ***
can225IgG *** *** *** *** *** ***
Dog IgE ISO ns ns *** * ns ***
can225IgE *** *** *** *** *** ns
Dog IgG 1 dog IgE ISO ns ns *** ns *** ***
can225IgG 1can225IgE ns ns *** ns *** ns
Statistical analysis was calculated by 2-way ANOVA and Bonferroni posttest. Significance is determined as following: ns, nonsignificant (P > .05).
*P < .05.
***P < .001.
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TABLE E5. Amino acid and coding DNA sequence of can225IgE-l
Sequence description Sequence
Can225IgE-l EPSILON chain
amino acid sequence
Legend:
Bold, dog immunoglobulin
heavy-chain variable region
leader (ACI25521.1)
Underlined, 225 variable region
Regular, dog immunoglobulin
epsilon constant region
MESVLGWVFLVAILQGVQGQVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGN
TDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAATSQDLSVFPLASCC
KDNIASTSVTLGCLVTGYLPMSTTVTWDTGSLNKNVTTFPTTFHETYGLHSIVSQVTASGKWAKQRFTCSVAHAESTA
INKTFSACALNFIPPTVKLFHSSCNPVGDTHTTIQLLCLISGYVPGDMEVIWLVDGQKATNIFPYTAPGTKEGNVTSTH
SELNITQGEWVSQKTYTCQVTYQGFTFKDEARKCSESDPRGVTSYLSPPSPLDLYVHKAPKITCLVVDLATMEGMNL
TWYRESKEPVNPGPLNKKDHFNGTITVTSTLPVNTNDWIEGETYYCRVTHPHLPKDIVRSIAKAPGKRAPPDVYLFLP
PEEEQGTKDRVTLTCLIQNFFPADISVQWLRNDSPIQTDQYTTTGPHKVSGSRPAFFIFSRLEVSRVDWEQKNKFTCQV
VHEALSGSRILQKWVSKTPGK
Can225IgE-l
EPSILON chain
DNA sequence
(HEK293-optimized)
Legend:
Bold, STOP codon
ATGGAAAGCGTGCTGGGCTGGGTGTTCCTGGTGGCCATTCTGCAGGGCGTGCAGGGACAGGTGCAGCTGAAGC
AGTCTGGCCCTGGACTGGTGCAGCCTAGCCAGAGCCTGAGCATCACCTGTACCGTGTCCGGCTTCAGCCTGAC
CAACTACGGCGTGCACTGGGTGCGCCAGAGCCCTGGAAAAGGCCTGGAATGGCTGGGAGTGATTTGGAGCGGC
GGCAACACCGACTACAACACCCCCTTCACCAGCAGACTGTCCATCAACAAGGACAACAGCAAGAGCCAGGTGT
TCTTCAAGATGAACAGCCTGCAGAGCAACGACACCGCCATCTACTACTGCGCTCGGGCCCTGACCTACTATGA
CTACGAGTTCGCCTACTGGGGCCAGGGCACACTCGTGACAGTGTCTGCCGCCACCAGCCAGGACCTGAGCGTG
TTCCCTCTGGCCAGCTGCTGCAAGGACAATATCGCCAGCACCAGCGTGACCCTGGGCTGCCTCGTGACCGGCT
ACCTGCCTATGAGCACCACAGTGACCTGGGACACCGGCAGCCTGAACAAGAACGTGACCACCTTCCCCACCAC
CTTTCACGAGACATACGGCCTGCACAGCATCGTGTCTCAAGTGACCGCCAGCGGCAAGTGGGCCAAGCAGAGA
TTCACATGCAGCGTGGCCCACGCCGAGAGCACCGCCATTAACAAGACCTTCAGCGCCTGCGCCCTGAACTTCA
TCCCTCCCACCGTGAAGCTGTTCCACAGCAGCTGCAACCCCGTGGGCGATACCCACACCACCATTCAGCTGCT
GTGCCTGATCAGCGGCTACGTGCCCGGCGACATGGAAGTGATCTGGCTGGTGGATGGCCAGAAGGCTACCAAC
ATCTTCCCCTACACCGCCCCTGGCACCAAAGAGGGCAATGTGACCAGCACCCACTCCGAGCTGAACATCACCC
AGGGCGAGTGGGTGTCACAGAAAACCTACACCTGTCAAGTGACATACCAGGGCTTCACCTTCAAGGACGAGGC
CCGGAAGTGCAGCGAGAGCGATCCTAGAGGCGTGACCTCCTACCTGAGCCCCCCTAGCCCTCTGGACCTGTAC
GTGCACAAGGCCCCCAAGATCACCTGTCTGGTGGTGGACCTGGCCACAATGGAAGGCATGAACCTGACCTGGT
ACAGGGAAAGCAAAGAACCCGTGAACCCAGGCCCTCTGAACAAAAAGGACCACTTCAACGGCACCATCACCGT
GACAAGCACCCTGCCCGTGAACACCAACGACTGGATCGAGGGCGAGACTTACTACTGCAGAGTGACCCACCCT
CATCTGCCCAAGGACATCGTGCGGTCTATCGCCAAGGCCCCAGGCAAAAGGGCCCCTCCCGATGTGTACCTGT
TCCTGCCTCCCGAGGAAGAACAGGGCACCAAGGACAGAGTGACACTGACCTGCCTGATCCAGAACTTCTTCCC
CGCCGACATCTCCGTGCAGTGGCTGAGAAACGACAGCCCCATCCAGACCGACCAGTACACCACCACCGGCCCT
CACAAGGTGTCCGGAAGCAGACCCGCCTTCTTCATCTTCAGCAGGCTGGAAGTGTCCCGGGTGGACTGGGAGC
AGAAGAACAAGTTCACATGCCAGGTGGTGCACGAGGCCCTGAGCGGCTCTCGGATCCTGCAGAAATGGGTGTC
CAAGACCCCCGGCAAGTGA
(Continued)
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TABLE E5. (Continued )
Sequence description Sequence
Can225IgE-l
LAMBDA chain
amino acid sequence
Legend:
Bold, dog immunoglobulin
lambda light-chain variable
region leader (XP_013963655.1)
Underlined, 225 light-chain
variable region
Regular, dog immunoglobulin
lambda constant region
MTSTMAWSSFLLTLLAHFTGSWADILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESI
SGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAQPKASPSVTLFPPSSEELGANK
ATLVCLISDFYPSGVTVAWKADGSPVTQGVETTKPSKQSNNKYAASSYLSLTPDKWKSHSSFSCLVTHEGSTVEKK
VAPAECS
Can225IgE-l
LAMBDA light-chain
DNA sequence
(HEK293-optimized)
Legend:
Bold, STOP codon
ATGACCAGCACAATGGCCTGGTCCAGCTTCCTGCTGACCCTGCTGGCCCACTTTACAGGCAGCTGGGCCGACATT
CTGCTGACACAGAGCCCCGTGATCCTGAGCGTGTCCCCTGGCGAGAGAGTGTCCTTCAGCTGCAGAGCCAGCCA
GAGCATCGGCACCAACATCCACTGGTATCAGCAGCGGACCAACGGCAGCCCCAGACTGCTGATTAAGTACGCCAG
CGAGTCCATCAGCGGCATCCCCAGCAGATTTTCCGGCAGCGGCTCCGGCACCGACTTCACCCTGAGCATCAACAG
CGTGGAAAGCGAGGATATCGCCGACTACTACTGCCAGCAGAACAACAACTGGCCCACCACCTTCGGAGCCGGCAC
CAAGCTGGAACTGAAGAGAACCGTGGCCCAGCCCAAGGCCAGCCCTAGCGTGACACTGTTCCCTCCAAGCAGCGA
GGAACTGGGCGCCAACAAGGCCACACTCGTGTGCCTGATCAGCGACTTCTACCCCAGCGGCGTGACCGTGGCCTG
GAAGGCTGATGGCTCTCCTGTGACCCAGGGCGTGGAAACCACCAAGCCCAGCAAGCAGTCCAACAACAAATACG
CCGCCAGCAGCTACCTGAGCCTGACCCCCGATAAGTGGAAGTCCCACAGCAGCTTCAGCTGTCTCGTGACCCACG
AGGGCAGCACCGTGGAAAAGAAAGTGGCCCCTGCCGAGTGCAGCTGATAG
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TABLE E6. PIPE primers used for ligation-free cloning can225IgE-l heavy- and light- chain sequences into pVitro-1 hygro
Primer name Sequence
can225IgE-l epsilon forward TACAGCTAGCTGGCCAGACATGATAAGATACATTGATGAG
can225IgE-l epsilon reverse TCCGGATTGCTTTGAATTAGCGGTGGCTTTCACAACACCT
can225IgE-l lambda forward AGGGATCCCGTACGCCTAGGAGCAGGTTTCCCCAATGACA
can225IgE-l lambda reverse ACCGGTTGCTTTGAATTAGCGGTGGTTTTCACAACACCTA
PIPE, Polymerase incomplete primer extension.
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